Ana Custodio
Overview
Explore the profile of Ana Custodio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Olmo-Garcia M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, et al.
Oncologist
. 2025 Feb;
30(2).
PMID: 39998905
Patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have impaired nutritional and physical performance due to the cancer pathophysiology and its treatment. The NUTRIGETNE study sought to characterize the nutritional status...
2.
Perez-Wert P, Fernandez-Hernandez S, Gamez-Pozo A, Arranz-Alvarez M, Ghanem I, Lopez-Vacas R, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39518924
Gastric adenocarcinoma (GA) is a significant global health issue with poor prognosis, despite advancements in treatment. Although molecular classifications, such as The Cancer Genome Atlas (TCGA), provide valuable insights, their...
3.
Ligero M, Hernando J, Delgado E, Garcia-Ruiz A, Merino-Casabiel X, Ibrahim T, et al.
BJC Rep
. 2024 Nov;
1(1):9.
PMID: 39516643
Background: More accurate predictive biomarkers in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are needed. This study aims to investigate radiomics-based tumour phenotypes as a surrogate biomarker of the tumour vasculature...
4.
Gutierrez-Sainz L, Heredia-Soto V, Rodriguez-Garcia A, Crespo Sanchez M, Serrano-Olmedo M, Molero-Luis M, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273323
Pancreatic ductal adenocarcinoma (PDAC) is characterized by its poor prognosis. The current challenge remains the absence of predictive biomarkers. Cytokines are crucial factors in the pathogenesis and prognosis of PDAC....
5.
Riesco-Martinez M, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, et al.
Nat Commun
. 2024 Aug;
15(1):6753.
PMID: 39117670
The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) is...
6.
Feliu J, Gamez-Pozo A, Martinez-Perez D, Perez-Wert P, Matamala-Luengo D, Vinal D, et al.
Br J Cancer
. 2024 Mar;
130(10):1670-1678.
PMID: 38486123
Background: The Colorectal Cancer Subtyping Consortium established four Consensus Molecular Subtypes (CMS) in colorectal cancer: CMS1 (microsatellite-instability [MSI], Immune), CMS2 (Canonical, epithelial), CMS3 (Metabolic), and CMS4 (Mesenchymal). However, only MSI...
7.
Arias-Martinez A, de Castro E, Gallego J, Arrazubi V, Custodio A, Fernandez Montes A, et al.
Clin Transl Oncol
. 2024 Feb;
26(7):1674-1686.
PMID: 38361134
Background: The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial differences...
8.
La Salvia A, Lens-Pardo A, Lopez-Lopez A, Carretero-Puche C, Capdevila J, Benavent M, et al.
Eur J Endocrinol
. 2023 Nov;
190(1):62-74.
PMID: 38033321
Objective: Metabolic profiling is a valuable tool to characterize tumor biology but remains largely unexplored in neuroendocrine tumors (NETs). Our aim was to comprehensively assess the metabolomic profile of NETs...
9.
Perez-Wert P, Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Lecumberri A, Cacho Lavin D, et al.
Gastric Cancer
. 2023 Nov;
27(1):131-145.
PMID: 37964032
Background: Gastroesophageal adenocarcinoma in young adults (GCYA) counts for 10-15% of diagnoses. Previous studies have mainly focused on surgical outcomes in patients with resectable tumors; however, systemic therapy for advanced...
10.
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, Macia-Rivas L, Arrazubi V, et al.
Ther Adv Med Oncol
. 2023 Mar;
15:17588359231157641.
PMID: 36895850
Background: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall...